Cronos GroupSTU:7CI -1.04%85 EV-to-FCF is 10.88 as of Jul. 05, 2026. GuruFocus rates STU:7CI with a GF Score™ of 85/100 and a GF Value™ of €3.09 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 561 Drug Manufacturers companies, Cronos Group ranks better than 75.94% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Cronos Group's Enterprise Value is €244.1 Mil.
Cronos Group's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was €22.4 Mil. Therefore, Cronos Group's EV-to-FCF for today is 10.88.
The historical rank and industry rank for Cronos Group's EV-to-FCF or its related term are showing as below:
STU:7CI'
s EV-to-FCF Range Over the Past 10 Years
Min: -321.22 Med: -7.72 Max: 16.75
Current: 10.93
During the past 12 years, the highest EV-to-FCF of Cronos Group was 16.75. The lowest was -321.22. And the median was -7.72.
STU:7CI's EV-to-FCF is ranked better than 75.94% of 561
companies
in the Drug Manufacturers industry
Industry Median: 20.85
vs STU:7CI: 10.93
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Cronos Group's PE Ratio (TTM) for today is calculated as:
Cronos Group's share price for today is €2.466.
Cronos Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.008.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Cronos Group EV-to-FCF Related Terms
Cronos Group EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Cronos Group's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Cronos Group's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cronos Group EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cronos Group's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Cronos Group's EV-to-FCF falls into.
Cronos Group's current Enterprise Value is €244.1 Mil.
Cronos Group's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €22.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cronos Group (STU:7CI) has a EV-to-FCF of 10.88 as of Jul. 05, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Cronos Group and its competitors. According to the industry distribution chart, Cronos Group ranks #135 out of 561 companies in the Drug Manufacturers industry, placing it in the top 24.1%.
Is Cronos Group's EV-to-FCF too high?
Cronos Group's current EV-to-FCF is 10.88. The Drug Manufacturers industry median EV-to-FCF is 20.85. Cronos Group's value of 10.88 is 47.8% below this industry median. Based on the distribution chart, Cronos Group ranks #135 out of 561 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Cronos Group has a GF Score™ of 85/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cronos Group's EV-to-FCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Cronos Group ranks #135 out of 561 companies for EV-to-FCF. This places Cronos Group in the top 24% of its industry — outperforming the majority of peers. The industry median EV-to-FCF is 20.85. Cronos Group's value of 10.88 is 47.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.85, based on 561 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cronos Group's current EV-to-FCF of 10.88 is 47.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Cronos Group and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cronos Group's current EV-to-FCF is 10.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cronos Group stock overvalued right now?
Based on GuruFocus' analysis, Cronos Group (STU:7CI) is currently considered Modestly Undervalued. The stock's GF Value™ is €3.09, compared to a current price of €2.47 — trading 20.2% below its estimated fair value. The current EV-to-FCF is 10.88 and 47.8% below the Drug Manufacturers industry median of 20.85. Cronos Group's overall GF Score™ is 85/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Cronos Group (STU:7CI), the current EV-to-FCF is 10.88 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cronos Group (STU:7CI) Overvalued in 2026?
Based on GuruFocus' analysis, Cronos Group stock appears to be undervalued.
The current stock price of €2.47 is trading 20.2% below its estimated GF Value™ of €3.09.
GuruFocus considers Cronos Group to be Modestly Undervalued.
Key valuation signals for STU:7CI:
EV-to-FCF: 10.88
GF Value™: €3.09 vs. price of €2.47 (20.2% below fair value)
Industry Position: 47.8% below the Drug Manufacturers median (#135 of 561)
No single metric tells the full story. See the STU:7CI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cronos Group Inc is a cannabinoid company committed to building disruptive intellectual property by advancing cannabis research, technology, and product development. With a passion for responsibly elevating the consumer experience, the company is building an iconic brand portfolio. Its diverse international brand portfolio includes Spinach, PEACE NATURALS, LIT, and Lord Jones. The company operates in Canada, Israel, and other countries, with the majority of its revenue generated from Canada.
85GF Score
Get the complete analysis for STU:7CI
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:7CI has been successfully added to your 
